Company ProfilePremium

Modern Dental Group Limited

Company Profile Analysis

Ticker: 3600.HK

ESOMAR 23 Corporate BadgeISO Certifications Badge
Modern Dental Group Limited - Company showcase

Year Founded & Workforce

1986

8,575 Employees

Modern Dental Group Limited logo

Modern Dental Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Modern Dental Group Limited Overview

Modern Dental Group is the world's largest listed, vertically integrated dental-laboratory network. It manufactures and distributes custom-made dental prostheses to dentists, clinics, hospitals and dental service organisations (DSOs) in more than 28 countries.

The business model has two layers:

  • A low-cost offshore production backbone of about 5,900 technicians, mainly in Dongguan (China), Thailand and Vietnam.

  • A layer of locally branded, customer-facing sales and service businesses: Permadental, Labocast, Elysee Dental, MicroDental, Modern Dental Pacific/Southern Cross, YZJ, Hexa Ceram and others.

The group is consolidating a fragmented, cottage-industry market by turning digitalisation, particularly intra-oral scanner adoption, into faster turnaround and lower unit cost. In FY2025 it delivered record revenue of HK$3.74bn, EBITDA of HK$938m and net profit of HK$601m, with net cash on its bank borrowings.

Europe is now just over half of revenue, while North America and Greater China are shrinking in share. The group remains a founding-family-controlled company with a combined chairman and CEO.


Company's own description (FY2025 results announcement and 1H2026 interim announcement). The Group describes itself as a leading global dental prosthetic device provider focused on custom-made prostheses. Its portfolio has three product lines:

  1. Fixed prosthetic devices, such as crowns and bridges.

  2. Removable prosthetic devices, such as dentures.

  3. "Others": orthodontic devices, sports guards, anti-snoring devices, raw materials, dental equipment (including intra-oral scanners), clear aligners, and educational events and seminars.

Per Note 1 of the 1H2026 interim statements, the Group is principally engaged in the production and distribution of dental prosthetic devices and other dental appliances, including clear aligners.

Independent characterisation. MDG is a B2B contract manufacturer of patient-specific medical devices. Each unit is a "case" made to a dentist's impression or digital scan. Its economics are shaped by four features.

Revenue model: - About 94% of revenue is product revenue from custom devices, priced per case. In FY2025 it sold 2.85m cases at an average selling price (ASP) of HK$1,229, or HK$1,479 excluding Hexa Ceram.

  • The balance (HK$232.9m in FY2025) is distribution revenue from raw materials and dental equipment, notably intra-oral scanners. It also includes revenue from the proprietary TrioClear aligner and from education services.

  • All revenue is recognised "at a point in time" on delivery. There is no material subscription or licensing revenue.

Value chain position: MDG sits between dental-materials and equipment makers upstream (zirconia, alloys, scanners, CAD/CAM mills and printers) and dental practices downstream. It captures the labour-intensive design-and-finish step. Local sales and service entities own the dentist relationship, while offshore hubs do the volume production. Digital files now travel electronically (35–43% of volume is "digital solution" cases), which removes the physical-impression bottleneck and favours scaled offshore producers.

Customer types: - Independent dentists and group practices.

  • Corporate dental groups and DSOs, especially in Australia and North America.

  • Public hospitals and government-related orders in Hong Kong.

  • Universities: the group runs an in-house lab at The University of Hong Kong's dental school.

  • Distributors.

  • No single customer exceeds 10% of revenue.

End-markets: - Restorative dentistry: crowns, bridges and implant restorations.

  • Prosthodontics: full and partial dentures.

  • Orthodontics: clear aligners and appliances.

  • Dental sleep medicine: anti-snoring and obstructive sleep apnoea (OSA) appliances.

  • Sports dentistry.

Demand drivers: - Ageing populations and the shift of dentists to digital workflows.

  • The cost advantage of offshore production for reimbursement-constrained payers, e.g. German statutory insurance co-payments and Australian insurers.

  • Consolidation of small labs.

Strategy

10.1 Stated strategy: recurring themes in the FY2025 annual results and 1H2026 interim. Management restates the same themes in each document; they are paraphrased below.

  1. Digitalisation as an irreversible industry trend that accelerates consolidation. Digital solution cases are about 35–43% of volume. Centralised digital workflows, scanner partnerships, proprietary solutions and education centres are described as raising entry barriers and driving margin expansion and share gains.

  2. Geographic production diversification. Mass-scale sites in China, Vietnam and Thailand plus onshore labs in the US, Europe and Australia are presented as a tariff and geopolitical hedge. Management contrasts this with competitors that rely on single-country manufacturing.

  3. A full "dental ecosystem" rather than a lab. Prosthetics plus aligners, scanners, sleep devices and education.

  4. Selective M&A, JVs and partnerships, with priority on TrioClear aligners and distribution networks.

  5. Investment in mass-scale production, AI, automation, R&D and digital innovation.

  6. Margin discipline. Exit low-margin segments in China, rationalise loss-making DSO accounts in North America, and focus on mid- and high-value customers.

10.2 Strategic initiatives in the last 24 months

10.3 Medium-term targets and guidance.

  • No quantitative medium-term revenue, margin or EPS targets are publicly disclosed.

  • The company guides only through positive profit alerts:

    • FY2025 alert (16 Mar 2026): revenue HK$3.675–3.775bn; EBITDA HK$920–950m; net profit HK$590–610m. Actuals came in within the ranges.

    • FY2023 alert (11 Mar 2024): revenue HK$3.125–3.225bn; net profit HK$390–410m.

Payout policy: - FY2024 press materials describe the payout ratio as "raised to 40%".

  • FY2025 DPS of 25.7 cents is about 40% of EPS of 63.7 cents.

  • 1H2026 DPS of 14.0 cents is about 35% of interim EPS.

Products & Services

The Group does not publish SKU-level specifications or price lists. The table below is organised by segment and brand, from filings, company releases and the brands' own trade communications. Pricing is per case and set by local brand; it is not centrally disclosed except as ASPs.

5.1 Fixed prosthetic devices (FY2025: 1,309,530 cases at an ASP of HK$1,684)

5.2 Removable prosthetic devices (FY2025: 844,068 cases at an ASP of HK$1,085)

5.3 Others

5.4 Brand architecture by region

Product Portfolio

OfferingDescription / capabilitiesTarget customerYear / statusPricing

Metal-ceramic (PFM) crowns & bridges

Porcelain fused to a cast-metal substructure; single units and multi-unit bridges

General dentists; insurance-driven markets (Germany, France)

Legacy core line

Per unit; ASP n.d. by type

Full-metal crowns & bridges

Cast alloy restorations

Posterior and economy segments

Legacy

Per unit

Metal-free crowns & bridges

All-ceramic (zirconia, glass-ceramic) restorations; growing share through CAD/CAM

Aesthetic and premium practices

Expanding with digital workflows

Per unit

Custom implant abutments & implant restorations

Patient-specific abutments and screw- or cement-retained crowns

Implant practices; DSOs

Prices in China affected by VBP from 2023

Per unit

Digital solution cases

Restorations designed from intra-oral scans and produced via centralised CAD/CAM. 1,039,188 cases in FY2025 (+32.7%) and 627,773 in 1H2026 (+29.2%).

Scanner-equipped clinics

35–43% of total volume (1H2026)

—
OfferingDescriptionTargetStatus

Full dentures

Conventional acrylic complete dentures

Elderly and edentulous patients; public-health channels

Core

Partial dentures (with metal framework)

Cast cobalt-chrome frameworks with acrylic teeth

General dentists

Core

Partial dentures (without metal framework)

Flexible or acrylic partials

Economy and aesthetic segments

Core

Digital dentures

CAD-designed, milled or printed dentures. Management cites these as the main European volume driver in FY2023–1H2026.

European practices

Launched in Europe over FY2023–2025 (exact year n.d.)

OfferingDescriptionTargetKey data

TrioClear

Proprietary clear-aligner brand; Dr Chan Ronald is director and CEO of the aligner business

General dentists and orthodontists in Europe, Asia and Australia

Revenue: FY2021 21.0; FY2022 25.8; FY2023 33.7; FY2024 47.6; FY2025 59.7; 1H2026 32.8 (+20.2%) HK$m

Digital Sleep Design appliance

Proprietary nylon oral appliance for obstructive sleep apnoea and snoring (Australia)

Dentists and sleep physicians

Acquired Feb 2025; FY2025 revenue contribution HK$21.2m since acquisition

Orthodontic appliances

Retainers, functional and removable appliances

Orthodontists

Part of "other custom-made devices" (697,485 cases in FY2025, ASP HK$548)

Sports guards / night guards

Custom mouthguards

Dentists, sports clubs

Within "other custom-made"

Intra-oral scanners and dental equipment

Distribution of third-party scanners through joint ventures and distribution agreements (FY2022 disclosure). Scanner sales in Europe rose 13.6% in FY2022.

Clinics digitising their workflow

Part of "Others" (HK$140.1m in 1H2026; increase attributed to dental equipment)

Raw materials

Resale of dental materials

Clinics and labs

Part of "Others"

Education and events

THINK DIGITAL education symposia; World Dental Forum (Beijing, 4th edition 2017); Hexa Ceram 30th-anniversary symposium (May 2025)

Dentists

Service revenue within "Others"

RegionBrands

Western Europe

Permadental & Semperdent (Germany/Netherlands), Labocast (France), Elysee Dental (Benelux, Scandinavia, Spain); MD3D Solutions (Emmerich, Germany, digital)

Hong Kong / China

Modern Dental Laboratory (HK); YZJ / Yangzhijing Dental Laboratory (Shenzhen)

North America

MicroDental Laboratories (US); Modern Dental USA; Quantum Dental Laboratory/Technologies (Canada); Essex Dental (Ontario, acquired 2026); other cited lab names include Sundance Dental and Peak Dental Solutions

Australia / NZ

Modern Dental Pacific; Southern Cross Dental; Andent; Digital Sleep Design

Southeast Asia / others

Hexa Ceram (Thailand); Apex Digital Dental (Malaysia); Modern Dental SG (Singapore); Modern Dental TW (Taiwan); Labo Ocean Indien (Indian Ocean)

Financial Narrative

All figures are in HK$m, IFRS and audited, from the final results announcements for FY2021–FY2025. "Operating income" is gross profit plus other income and gains, less selling, administrative and other operating expenses, before finance costs and associates. It is analyst-derived and reconciles exactly to reported profit before tax.

6.1 Income statement

DPS composition: - FY2021: interim 7.5 + special 5.0 + final 4.4

  • FY2022: 3.7 + 4.4

  • FY2023: 6.0 + 9.0

  • FY2024: 8.0 + 9.2

  • FY2025: 10.7 + 15.0

6.2 Margins (%)

Revenue CAGR FY2021–FY2025: about 6.0% a year in HK$. In original currencies the CAGR is higher, because FY2022 included a 10.3% EUR and 6.8% AUD depreciation against HK$. Net-profit CAGR over the same period is about 13.6%.

6.3 Balance sheet (31 December, HK$m)

At 30 Jun 2026 (unaudited): - Cash HK$828.9m; bank borrowings HK$445.9m, giving net bank cash of HK$383.3m.

  • Leases HK$163.5m; total equity HK$3,540.2m; goodwill HK$1,294.0m; intangibles HK$365.9m.

  • Put-option liabilities (Hexa Ceram and Digital Sleep minorities) HK$83.7m.

  • Company gearing ratio 6%.

6.4 Cash flow (HK$m)

Capex notes: - FY2021 and FY2024 are property, plant and equipment (PP&E) additions, used as a proxy because a "capital expenditure" figure was not separately stated in the documents reviewed.

  • FY2022, FY2023 and FY2025 are the company's stated capex.

  • FY2025 acquisition outflows (Hexa Ceram HK$196.1m net; Digital Sleep HK$14.8m) are excluded from capex.

1H2026 cash flow (unaudited): OCF HK$330.2m (1H2025: 289.7); capex HK$34.5m; dividends paid HK$140.2m; buyback HK$3.7m; Essex Dental net outflow HK$15.7m.

6.5 Ratios (analyst-derived)

6.6 Trend commentary.

  1. FY2021 to FY2022: COVID inflection. FY2021 was a post-COVID rebound year: revenue +34.9%, EBITDA HK$626m. FY2022 then fell sharply: net profit −38.8%, gross margin down 3.6 points to 48.9%. Management cites:

    • Under-utilised capacity from the Q1 2022 Mainland China production suspension and recurring outbreaks.

    • Euro (−10.3%) and AUD (−6.8%) depreciation against HK$.

    • A mix shift towards lower-margin scanner sales. Operating cash flow halved, also because tax paid rose by HK$54.3m.

  2. FY2023: digital re-rating. Revenue rose 12.1% and gross margin recovered 4.7 points to 53.6%. Drivers were utilisation, a rising digital-case share (Mainland-produced digital cases +55.9% to 857k) and RMB weakness against HK$, which lowered the China-based cost base. Net profit rose 82.4%.

  3. FY2024: plateau. Revenue +6.1% but net profit only +1.2%. Costs absorbed HK$15.5m of acquisition costs, HK$14.2m of relocation costs and HK$26.2m of FX losses, while finance costs peaked at HK$51.7m on higher HIBOR. Adjusted EBITDA still grew 6.9%.

  4. FY2025: step-change. Revenue +11.1%, gross margin +2.3 points to 55.8%, EBITDA +32.4%, net profit +47.7%. Management cites three causes:

    • Efficiency from digital cases.

    • EUR appreciation against RMB and HK$ from April 2025. This is a structural natural hedge: euro revenue against a renminbi cost base.

    • Geographic mix: higher-margin Europe and Australia grew 15.5%, while lower-margin US and Greater China each fell about 7%. Hexa Ceram added HK$215.8m of revenue and HK$24.8m of profit but dilutes gross margin. FX turned from a HK$26.2m loss to a HK$23.5m gain, and other operating expenses fell 68.8%.

  5. 1H2026: margin expansion without FX help. Gross margin was 58.1% and the net margin 18.6%. Other operating expenses now include an FX loss of HK$14.1m, so the improvement is operational. Finance costs nearly halved to HK$11.6m. The group became net cash on bank debt from FY2023, and by mid-2026 its net cash was HK$383m.

  6. Watch item: working capital. Trade receivables rose to HK$821.8m at 30 Jun 2026 from HK$698.6m at end-2025. Receivables aged more than three months reached HK$256.4m (31% of the total). The cash conversion cycle has drifted up from 81.5 to 94.5 days over five years.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsRepresentative products

Fixed prosthetic devices

Restorative devices: crowns, bridges and implant restorations

Metal-ceramic, full-metal and metal-free (e.g. zirconia) crowns and bridges; custom implant abutments; implant-borne restorations

Removable prosthetic devices

Full and partial dentures, with or without metal frameworks

Conventional and digital (milled/printed) dentures; cast-metal partials

Others

Orthodontic devices, sports guards, anti-snoring devices, raw materials, dental equipment (including intra-oral scanners), clear aligners, education services

TrioClear aligners; Digital Sleep nylon OSA appliance; scanner distribution; THINK DIGITAL symposia

Revenue by Segment

SegmentFY2021FY2022FY2023FY2024FY2025

Fixed prosthetic devices revenue (HKD Mn)

1,936.01,803.51,985.02,048.62,205.3

Removable prosthetic devices revenue (HKD Mn)

537.4535.1713.0799.0916.0

Others revenue (HKD Mn)

481.8491.5474.0516.4615.2

Total revenue (HKD Mn)

2,955.22,830.13,172.03,364.03,736.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment and Segment Margins & Growth (%)

SegmentFY2021FY2022FY2023FY2024FY2025

Fixed gross profit (HKD Mn)

1,053.5922.51,093.01,129.61,282.1

Removable gross profit (HKD Mn)

293.6268.9387.1438.3495.7

Others gross profit (HKD Mn)

203.6191.9220.6231.0307.2

Fixed gross margin (%)

54.451.255.155.158.1

Removable gross margin (%)

54.650.354.354.954.1

Others gross margin (%)

42.339.046.544.749.9

Segment Margins & Growth (%) and Revenue by Segment (%)

SegmentFY2023FY2024FY2025

Fixed YoY growth (%)

10.13.27.6

Removable YoY growth (%)

33.212.114.6

Others YoY growth (%)

-3.68.919.1

Fixed share of revenue (%)

62.660.959.0

Removable share of revenue (%)

22.523.824.5

Others share of revenue (%)

14.915.416.5

Revenue by Segment (1H2025 revenue–1H2026 revenue)

Segment (HKD Mn unless stated)1H2025 revenue1H2026 revenue1H2026 gross profit1H2026 gross margin (%)

Fixed

1,098.31,184.7721.961.0

Removable

447.4492.9276.556.1

Others

289.1354.9182.451.4

Total

1,834.82,032.51,180.958.1

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (HKD Mn)

2,955.22,830.13,172.03,364.03,736.5

Revenue growth (%)

34.9-4.212.16.111.1

Gross profit (HKD Mn)

1,550.71,383.31,700.71,798.92,085.0

Selling & distribution expenses (HKD Mn)

359.5375.0414.1456.2482.5

Administrative expenses (HKD Mn)

697.3702.2747.9762.1852.8

Operating income (HKD Mn, derived)

486.6316.0551.1579.9793.9

EBITDA (HKD Mn, company-defined)

626.4463.4694.5708.8938.1

Adjusted EBITDA (HKD Mn, non-IFRS)

628.7464.8693.9741.5941.8

Depreciation & amortisation (HKD Mn)

140.4148.1145.5139.2149.1

Finance costs (HKD Mn)

23.126.341.251.734.4

Profit before tax (HKD Mn)

464.1290.1509.6527.1759.5

Income tax (HKD Mn)

103.769.6107.4120.2158.3

Net profit (HKD Mn)

360.4220.5402.2406.9601.2

Profit attributable to owners (HKD Mn)

360.8220.5404.1408.0597.0

Basic EPS (HK cents)

37.723.142.443.263.7

Diluted EPS (HK cents)

37.723.142.443.263.7

Dividend per share (HK cents)

16.98.115.017.225.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

52.548.953.653.555.8

Operating margin (%, derived)

16.511.217.417.221.2

EBITDA margin (%)

21.216.421.921.125.1

Net margin (%)

12.27.812.712.116.1

Effective tax rate (%, derived)

22.324.021.122.820.8

Balance Sheet and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (HKD Mn)

3,657.43,539.13,952.84,074.94,540.3

Cash & cash equivalents (HKD Mn)

633.2444.4697.7816.8767.0

Bank borrowings: current (HKD Mn)

173.484.963.7115.970.9

Bank borrowings: non-current (HKD Mn)

499.7545.3612.5621.2407.4

Total bank borrowings (HKD Mn)

673.1630.2676.2737.2478.2

Lease liabilities (HKD Mn)

160.0158.0176.0187.1175.9

Net bank debt (HKD Mn; negative = net cash)

35.1182.5-21.7-79.9-289.0

Net debt incl. leases (HKD Mn)

195.1340.5154.3107.2-113.1

Total equity (HKD Mn)

2,358.72,333.52,643.12,725.63,295.6

Equity attributable to owners (HKD Mn)

2,348.42,320.02,632.32,715.93,288.8

Goodwill (HKD Mn)

1,185.71,132.41,159.61,098.91,286.7

Intangible assets (HKD Mn)

255.2228.2214.6200.4362.9

Goodwill + intangibles as % of total assets (%)

39.438.434.831.936.3

Net current assets / working capital (HKD Mn)

727.1736.41,016.41,170.31,252.9

Company gearing ratio (%, company definition)

1822161410

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (HKD Mn)

525.1258.3575.8521.2763.1

Capital expenditure (HKD Mn)

135.2185.4159.7139.872.0

Free cash flow (HKD Mn, OCF less capex)

389.972.9416.0381.3691.1

Lease principal payments (HKD Mn)

54.158.061.260.557.2

Dividends paid (HKD Mn)

186.577.599.0160.7189.3

Share buybacks (HKD Mn)

7.93.620.225.130.5

Net investing cash flow (HKD Mn)

-142.7-227.9-155.0-145.5-278.1

Net financing cash flow (HKD Mn)

-452.1-201.8-173.6-227.7-575.7

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%, net profit / average total equity)

15.69.416.215.220.0

ROA (%, net profit / average total assets; FY2021 year-end basis)

9.96.110.710.114.0

ROIC (%, NOPAT / equity + bank debt + leases − cash)

14.89.015.515.819.8

Current ratio (x)

2.092.392.833.023.24

Bank debt / equity (x)

0.290.270.260.270.15

Net bank debt / EBITDA (x)

0.060.39-0.03-0.11-0.31

Interest coverage (x, operating income / finance costs)

21.112.013.411.223.1

Asset turnover (x)

0.810.790.850.840.87

Days sales outstanding (days)

65.373.067.966.668.2

Days inventory outstanding (days)

37.039.741.239.545.2

Days payables outstanding (days)

20.819.119.915.318.9

Cash conversion cycle (days)

81.593.689.290.894.5

Revenue by Region

RegionFY2021FY2022FY2023FY2024FY2025

Europe revenue (HKD Mn)

1,254.61,180.61,399.41,618.41,886.8

North America revenue (HKD Mn)

718.8709.3753.6752.1696.4

Greater China revenue (HKD Mn)

699.2666.7713.6662.2615.4

Australia revenue (HKD Mn)

250.3235.8254.3264.8289.1

Others revenue (HKD Mn)

32.237.751.166.5248.9

Revenue by Region (%)

RegionFY2021FY2022FY2023FY2024FY2025

Europe share (%)

42.541.744.148.150.5

North America share (%)

24.325.123.822.318.6

Greater China share (%)

23.723.622.519.716.5

Australia share (%)

8.58.38.07.97.7

Others share (%)

1.01.31.62.06.7

Region Margins & Growth (%)

RegionFY2022FY2023FY2025

Europe, EUR growth (%)

4.915.311.8

North America, US$ growth (%)

-1.36.2-7.4

Greater China growth (%)

-0.611.9-7.1

Australia, AUD growth (%)

1.112.811.8

Others growth (%)

17.035.6274.1

Geographic Revenue

Region1H2025 (HKD Mn)1H2026 (HKD Mn)Original-currency growth (%)Share 1H2026 (%)

Europe

920.31,093.310.953.8

North America

365.7331.3-9.416.3

Greater China

293.2300.0

Mainland +0.9; HK −8.5

14.8

Australia

137.9162.86.38.0

Others

117.8145.2

23.2 (HK$)

7.1

Share Price History

DatePrice (HKD)Source / context

15 Dec 2015

4.20

IPO price

5-year high (period about 2021)

11.00

Market-data 5-year range high

Sep–Nov 2022

1.67–2.08

Company buyback range (5-year low area of about 1.60)

May–Dec 2023

2.32–3.80

Company buyback range

Jan–Jul 2025

3.73–4.37

Company buyback range

27 Nov 2025

5.21

Close before option grant

24 Dec 2025

5.45

etnet quote

29 May 2026

5.87

Press report after Q1 update; market cap HK$5.488bn

Jun 2026

5.79

Company buyback price

Undated, about Q3 2026

7.62

Market-data snapshot (YTD about +43%; 52-week range 4.33–8.00)

Valuation Multiples

MultipleAt HK$5.87 (29 May 2026)At HK$7.62 (latest snapshot)

Market cap (HKD Mn)

5,4887,120

EV (HKD Mn; mkt cap − net bank cash + leases + put liabilities + NCI)

≈5359

≈6991

P/E TTM (x)

8.010.4

EV/EBITDA TTM (x)

5.16.7

EV/Sales TTM (x)

1.361.78

P/B (x, on equity attributable to owners of HK$3,533.7m)

1.552.01

Dividend yield TTM (%, 29.0 cents)

4.93.8

Analyst Ratings & Targets

Broker / sourceDateRatingTarget (HKD)Basis

CGSI (China Galaxy Securities International)

18 Sep 2025

Add

6.88

10x FY26F P/E; FY25F net profit HK$545m (actual HK$601m)

Stockopedia consensus

about mid-2026

—6.88

Single-broker consensus

Simply Wall St forecast

Apr 2025

——

Revenue growth about 13% a year over 2 years (now dated)

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025

Interim DPS (HK cents)

7.53.76.08.010.7

Special DPS (HK cents)

5.00.00.00.00.0

Final DPS (HK cents)

4.44.49.09.215.0

Total DPS (HK cents)

16.98.115.017.225.7

Payout ratio (%, DPS / basic EPS)

44.835.135.439.840.3

Dividends & Capital Returns and Share Count (m)

MetricFY2021FY2022FY2023FY2024FY2025

Buyback spend (HKD Mn)

7.93.620.225.130.5

Shares repurchased (m)

—1.956.69—7.33

Debt Maturity Profile

Maturity31 Dec 202530 Jun 2026

Within 1 year

70.978.4

Second year

80.985.9

Third to fifth years

326.5281.6

Total

478.2445.9

Analyst Conclusions

Management guidance.

  • No numeric guidance.

  • The qualitative outlook (1H2026) is:

    • Sustained momentum and further market-share gains from digitalisation.

    • Margin expansion from automation and AI.

    • Selective M&A, especially in aligners.

    • Tariff resilience through China, Vietnam and Thailand production.

    • Continued mid- to long-term optimism on China as VBP standardises pricing.

Consensus growth. Thin coverage. The last published broker forecast (CGSI, Sep 2025) was FY2025 net profit of HK$545m, which actual results beat by about 10%. Current FY2026 and FY2027 consensus is n.d.

Run-rate. 1H2026 annualised implies about HK$4.0bn revenue and roughly HK$750m net profit if H2 is seasonally similar (analyst extrapolation, not guidance). For comparison, H2 2025 revenue was HK$1,901.7m and net profit HK$312.6m.

Bull case

  1. Structural margin step-up. Gross margin of 58.1% and net margin of 18.6% in 1H2026 were achieved despite an FX headwind, which points to operating leverage from more than 1m digital cases a year rather than currency luck.

  2. Underpriced compounder. Net profit grew at about 13.6% CAGR over FY2021–25 and ROIC is about 20% with net cash. Yet the stock trades at about 10x trailing P/E and about 6.7x EV/EBITDA, with a dividend yield of about 4%.

  3. Optionality from consolidation. Net bank cash of HK$383m, a proven bolt-on playbook (Hexa Ceram earned HK$24.8m profit in year one) and a fragmented market support accretive roll-ups. The higher-growth adjacencies are aligners (+20%) and sleep devices.

Bear case

  1. Geographic decay outside Europe. North America and Greater China fell from 46% of revenue in FY2023 to 31% in 1H2026. Both are shrinking, and the North American onshore asset (MicroDental) earns thin profits against a goodwill-heavy balance sheet.

  2. Weak organic volume. Excluding Hexa Ceram, FY2025 volume grew only 2.4%. Margin gains partly reflect cheap RMB labour and favourable EUR crosses that can reverse; FX already swung to a loss in 1H2026.

  3. Governance discount is justified. Family control of about 51% plus a combined chair/CEO, option grants without performance conditions to family directors, and a free float of about 32% will cap institutional ownership and the re-rating.

Key catalysts and monitorables (next 12 months)

  • 9M2026 operating update (expected about late Nov 2026): organic volume and ASP excluding acquisitions.

  • FY2026 positive profit alert (about mid-Mar 2027) and FY2026 results (about late Mar 2027): whether the gross margin above 58% holds in H2.

  • North America: whether the DSO rationalisation finishes and MicroDental stabilises; tariff policy changes.

  • China: whether the Mainland's positive turn (+0.9% in 1H2026) persists, and whether Hong Kong leakage abates.

  • EUR/RMB and EUR/HK$ cross-rates.

  • M&A announcements, especially aligner-related, and exercise of the Hexa Ceram/Digital Sleep put/call options.

  • Receivables quality: ageing above 3 months and the DSO trend.

  • Grants under the 2026 Share Award and Option schemes, and their dilution.

Analyst verdict. Modern Dental Group has spent five years turning a labour-arbitrage dental-lab network into a digitally routed manufacturing platform, and FY2025–1H2026 is where that work showed up in the numbers.

  • Gross margin moved from 48.9% in FY2022 to 58.1% in 1H2026.

  • Net margin more than doubled.

  • Free cash flow approached HK$700m.

  • The balance sheet moved to net cash on bank debt.

These are institutional-quality metrics. They have been achieved while two of the group's four major regions, North America and Greater China, were contracting. That says something about the strength of the European franchise (50–54% of revenue, growing 11–12% in euros) and about the efficiency of the Dongguan–Thailand–Vietnam production triangle.

The central analytical tension is quality of growth versus quality of margins:

  • Reported revenue growth of about 11% is flattered by acquisitions; organic volume excluding Hexa Ceram grew roughly 2%.

  • FY2025's profit surge had a real FX tailwind.

  • 1H2026 matters because the margin expansion continued with FX turning negative. On balance, that supports the view that digital-case economics are structural.

Valuation looks undemanding. At about 10x trailing earnings and under 7x EV/EBITDA, with a roughly 4% yield and about 20% ROIC, the market is applying a heavy discount. The reasons are family control, a combined chair/CEO, thin sell-side coverage and an illiquid free float. That discount is partly deserved and unlikely to close quickly. Even so, it leaves room for returns driven by earnings growth and dividends.

Stance: constructive, with an emphasis on monitoring.

  • The thesis holds while the gross margin stays above about 56%, Europe compounds at high single digits or better in euros, and North America stabilises after the DSO clean-up.

  • The thesis is challenged by a FX-driven margin reversal, rising receivables ageing, or a large, poorly priced acquisition.

Treat price and consensus data as provisional until checked against a live terminal.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackground / educationAgeTotal remuneration

Dr Chan Ronald Yik Long

Chairman (since 31 Mar 2021), CEO (since 1 Jan 2025), executive director (since 19 Jun 2015)

Joined 2014

BSc (Biological Sciences), University of Calgary (2008); BDS, HKU (2014); MBA, Heriot-Watt (2015); MSc Aesthetic Restorative Dentistry, Manchester (2019). Registered dentist in Hong Kong; Hon. Clinical Assistant Professor at HKU (since 2022); Hong Kong Young Industrialist Award (2021). Leads Southeast Asia strategy and the clear-aligner business.

38 (Dec 2024 announcement)

About HK$6.41m (third-party aggregation of the latest annual report); 9.3m options granted Nov 2025

Ms Chan Yik Yu

Executive director (since 19 Jun 2015); Chief Marketing Officer

Joined 2014

University of Calgary graduate (2010); vice-chairman and deputy GM of a subsidiary; director of Triera Holdings

38

About HK$3.76m; 9.3m options

Mr Chan Kwun Pan

Executive director

Group founder generation

Father of Dr Chan Ronald and Ms Chan Yik Yu

About 68

About HK$3.74m; 0.93m options

Mr Chan Chi Yuen

Executive director

—

Cousin of Dr Chan Ronald

About 41

About HK$3.75m; 0.93m options

Mr Chan Kwun Fung

Non-executive director (re-designated from executive, about Apr 2025)

Joined Nov 1991; director since Jul 2012

Controlling-family patriarch; director of Triera Holdings

70 (Mar 2025)

About HK$3.74m; 0.93m options

Dr Cheung Wai Bun Charles, J.P.

INED; Audit Committee chair

Since Dec 2015

——

About HK$0.36m

Dr Chan Yue Kwong Michael

INED; Nomination Committee chair

Since Dec 2015

——

About HK$0.36m

Dr Yau Ka Po

INED; Remuneration Committee chair (from 15 Dec 2025)

About 4 years

——

About HK$0.36m

Executive Leadership Team

NameTitleNotes

Mr Kwan Ngai Kit

CFO and Company Secretary

Since 25 Oct 2016; about 46

Mr August Wilhelm Torsten Schwafert

CEO, Modern Dental Europe BV

Per market-data profiles; current status n.d.

Mr Gregory Scialom

President, Labocast SAS

Per market-data profiles

Mr James Squirrell

CEO, Modern Dental Pacific Pty Ltd

Per market-data profiles

Mr Kwan Chi Hang Thomas

Employee (option grantee)

Spouse of Ms Chan Yik Yu; received 0.93m options

Richie Leung

Business Director, Modern Dental South East Asia

Per 2024 trade interview

Board & Management Changes

DateChangeContext

1 Jul 2022

Ngai Chi Ho Alwin resigns as Vice-Chairman, executive director and COO

Personal reasons (leaving Greater China)

31 Dec 2024 / 1 Jan 2025

CEO Ngai Shing Kin retires; Dr Chan Ronald appointed CEO

Generational transfer to the Chan family's second generation; chair/CEO combined

About Apr 2025

Chan Kwun Fung re-designated as non-executive director

Founder steps back from executive duties

15 Dec 2025

Dr Cheung Wai Man William retires as INED

To focus on FDI World Dental Federation commitments; no disagreement

26 Mar / 28 May 2026

2026 Share Award Scheme adopted; 2026 Share Option Scheme adopted at AGM

Replaces the expired 2015 option scheme and 2015 RSU scheme

Major Shareholders

HolderShares (m)Stake (%)Date

Chan Kwun Fung & family (incl. Triera Holdings)

474.3950.74

15 Aug 2025

Ngai Shing Kin (former CEO)

98.0410.49

15 Aug 2025

Ngai Chi Ho Alwin (former COO)

63.126.75

15 Aug 2025

Top-10 institutional holders

——

Not in sources reviewed

Competitive Landscape

Key Competitors

CompetitorTypeOverlap with MDGRevenue / scaleRelative positioning

Glidewell Laboratories (US)

Private lab and materials group

Fixed and removable prosthetics in the US

n.d. (private)

Largest US lab; vertically integrated into materials and milling; competes with MicroDental

National Dentex Labs / NDX (US)

Private lab network

US fixed and removable; DSO accounts

n.d. (private)

Consolidator rival in North America

Flemming Dental (Germany)

Private lab network

German fixed and removable

—

Domestic rival to Permadental

Protilab (France)

Offshore-production lab

French offshore crowns and bridges

—

Direct price competitor to Labocast

Small independent labs (Europe, US, Australia, China)

Thousands of micro-labs

All segments

—

MDG's main share donor as digitisation consolidates the market

Mainland China domestic labs (various)

Private

China fixed and implant prosthetics under VBP

—

Drove "prolonged intense price competition" in FY2024–25

Align Technology (US)

Listed OEM

Clear aligners vs TrioClear; iTero scanners

FY2024 revenue about US$4.0bn

Category leader; TrioClear is a niche follower

Angelalign Technology (HK: 6699)

Listed aligner OEM

Aligners in China and Asia

—

Aligner competitor in Asia

Dentsply Sirona (US)

Listed OEM

Chairside CAD/CAM (CEREC) substitutes lab crowns; aligners (SureSmile)

FY2024 revenue about US$3.8bn

Chairside milling is a disintermediation threat

Straumann Group (CH)

Listed OEM

Implant components, aligners (ClearCorrect), digital workflows

FY2024 revenue about CHF 2.5bn

Supplier and partial competitor

Envista (US)

Listed OEM

Spark aligners; scanners (Nobel/Ormco)

FY2024 revenue about US$2.5bn

Adjacent

Peer Comparison FY2025

MetricModern Dental (FY2025)Align Technology (FY2024)Dentsply Sirona (FY2024)Straumann (FY2024)

Revenue

HK$3,737m (≈US$480m)

≈US$4.0bn

≈US$3.8bn

≈CHF 2.5bn

Revenue growth

+11.1%

n.d. here

n.d. here

n.d. here

Gross margin

55.8%

n.d. here

n.d. here

n.d. here

EBITDA margin

25.1%

n.d. here

n.d. here

n.d. here

R&D % of revenue

1.0%

n.d. here

n.d. here

n.d. here

Recent Developments

Headcount rose to 8,575.

Company Snapshot

$479.7M

Revenue

8,575

Employees

1986

Founded

Kowloon, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Record profitability with an expanding margin. Gross margin: 48.9% (FY2022), 55.8% (FY2025), 58.1% (1H2026). Net margin: 7.8% (FY2022) to 18.6% (1H2026).
  • Fortress balance sheet. Net bank cash grew from HK$21.7m (FY2023) to HK$289.0m (FY2025) and HK$383.3m (30 Jun 2026). Company gearing ratio is 6%.
  • Strong cash generation. FY2025 OCF of HK$763.1m is 127% of net profit; FY2025 FCF is HK$691.1m.
  • Digital leadership. Digital cases rose from 301k (FY2021) to 1.04m (FY2025), and are 35–43% of volume.
  • Diversified production. About 3,700 technicians in China, 1,300 in Thailand and 180 in Vietnam, plus onshore labs.
  • Dominant European franchise. Europe revenue of HK$1,887m in FY2025 is 50.5% of the group and grew 11.8% in EUR.
  • Shareholder returns. DPS rose from 8.1 cents (FY2022) to 25.7 cents (FY2025). Buybacks were about HK$80m over FY2021–1H2026.

Weaknesses

  • North American underperformance. Revenue fell from HK$753.6m (FY2023) to HK$696.4m (FY2025); 1H2026 was −9.4%; MicroDental was −12.7%.
  • Greater China erosion. Revenue fell from HK$713.6m (FY2023) to HK$615.4m (FY2025); Hong Kong was −11.5% in FY2025.
  • Low organic volume growth excluding acquisitions. FY2025 volume ex-Hexa grew +2.4%; 9M2025 +1.6%.
  • Low R&D intensity: 1.0% of revenue in FY2025.
  • Rising receivables. Trade receivables reached HK$821.8m at 30 Jun 2026 (+17.6% in six months), and receivables older than one year were HK$58.8m.
  • Governance concentration. Combined chair/CEO; family directors hold 5 of 8 seats; options carry no performance conditions.
  • Goodwill-heavy balance sheet. Goodwill and intangibles of HK$1,659.9m are 36% of total assets.

Opportunities

  • Consolidation of small labs as digitalisation raises the capital bar. Management explicitly targets share gains.
  • TrioClear aligner scale-up: revenue of HK$59.7m in FY2025 (+25.5%) and +20.2% in 1H2026.
  • Dental sleep medicine via Digital Sleep (FY2025 revenue contribution HK$21.2m).
  • Southeast Asian growth: "Others" region grew 23.2% in 1H2026 (Thailand, Singapore, Malaysia).
  • China VBP normalisation: Mainland sales turned positive (+0.9%) in 1H2026, and management expects standardised pricing to reward scale.
  • Margin leverage from automation, AI and Vietnam/Thailand capacity. Administrative costs fell from 22.8% to 21.4% of revenue in 1H2026.

Threats

  • US tariff escalation affecting imported prosthetics; the US import unit is only +1.4%.
  • FX reversal. FY2025 profit benefited from EUR appreciation against RMB and HK$, and 1H2026 already shows an FX loss of HK$14.1m.
  • Chairside CAD/CAM and in-office printing disintermediating simple restorations.
  • Implant VBP-style price controls spreading in China or to other public payers.
  • Hong Kong demand leakage to Shenzhen clinics (Hong Kong −8.5% in 1H2026).
  • Goodwill impairment risk in North America. Impairment-test pre-tax discount rates are 14–20%, and the MicroDental profit base is thin.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
27 Mar 2025FY2024 results: revenue HK$3,364.0m (+6.1%), net profit HK$406.9m (+1.2%), final DPS 9.2 cents; payout described as raised to 40%Baseline before FY2025 step-up
27 Mar 2025Chan Kwun Fung re-designated from executive to non-executive director (effective about 1 Apr 2025)Founder steps back
Apr 2025US tariffs implemented, creating uncertainty for the US import businessBecame a stated FY2025 headwind
Apr–Jul 2025Share repurchases: 5.63m shares, HK$3.73–4.37Capital return at about 6–7x forward earnings
28 May 2025Hexa Ceram 30th-anniversary symposium (Thailand)Integration and brand building
29 May 2025AGM; repurchase mandate renewedRoutine
14 Aug 2025Positive profit alert for 1H2025Pre-announced strong half
28 Aug 20251H2025 interim: revenue HK$1,834.8m (+7.8%), net profit HK$288.7m (+34.7%), interim DPS 10.7 centsMargin inflection confirmed
18 Sep 2025CGSI (China Galaxy Securities International) reiterates "Add", target raised to HK$6.88 (10x FY26F P/E)Sell-side support
9 Oct 2025Interim dividend paid—
27 Nov 20259M2025 update: revenue HK$2,752m (+9.2%); volume 2.115m cases (+29.5%; +1.6% ex-Hexa); ASP ex-Hexa HK$1,474, flatOrganic volume growth modest
28 Nov 202523.25m share options granted at HK$5.11, 18.6m of them to two family directorsGovernance scrutiny: no performance conditions
12 Dec 2025INED Dr Cheung Wai Man William to retire on 15 Dec 2025; committee reshuffleBoard refresh
14 Dec 20252015 Share Option Scheme expiresTriggers new schemes
12 Feb 202640th-anniversary rebrand: "Redefining Smiles. The Digital Way."Positioning shift to digital
16 Mar 2026Positive profit alert for FY2025 (net profit +45–50%)Pre-announcement
26 Mar 2026FY2025 results: record revenue HK$3,736.5m, EBITDA HK$938.1m, net profit HK$601.2m; final DPS 15.0 centsRecord year
26 Mar 20262026 Share Award Scheme adopted; new option scheme proposedLong-term incentive framework
23 Apr 20262025 Annual Report and 2025 ESG Report published; AGM circularDisclosure
28 May 2026AGM; 2026 Share Option Scheme adopted—
28 May 2026Q1 2026 voluntary update: revenue about HK$988m (+12.1%), a record quarter; strong Europe, weak North AmericaMomentum confirmed; shares +4.8% to HK$5.87 on 29 May
4 Jun 2026Essex Dental (Ontario) acquisition completedNorth American bolt-on
Jun 2026Repurchased 636,000 shares at HK$5.79—
30 Jun 2026FY2025 final dividend paid (HK$140.2m)—
12 Aug 2026636,000 repurchased shares cancelledShare count 934.214m
27 Aug 20261H2026 interim: revenue HK$2,032.5m (+10.8%), gross margin 58.1%, net profit HK$377.6m (+30.8%), interim DPS 14.0 centsRecord half; North America DSO rationalisation disclosed
Late Aug – Sep 2026Third-party commentary flags P/E of about 11x versus peers; muted price reactionValuation debate
9 Oct 2026Interim dividend of HK14.0 cents payable—

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue rose from HKD 2,955.2 Mn in FY2021 to HKD 3,736.5 Mn in FY2025.
Modern Dental Group Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue2,955.22,830.13,1723,3643,736.5
Gross profit1,550.71,383.31,700.71,798.92,085

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.